Waypoint Bio
Recent Finacing
Series A
Recent Raise
$20M
Waypoint Bio builds AI models and an in‑house spatial pooled in vivo screening platform to design and validate CAR‑T and in vivo delivery vector cell therapies for solid tumors.
Highlights
Focus Areas
Biotechnology
Computer Vision
Machine Learning
Recent Investors
Financials
$39M
Total Raised
3
Funding rounds
8
Investors